

MetaboAD

Metabolomics-Driven Biomarker Discovery of Alzheimer's Disease

This project seeks to identify new biomarkers or biomarker profiles for Alzheimer's disease (AD).

We will also investigate which biomarkers in AD patients are related to poor brain clearance function using animal models. This bridge back to preclinical research will facilitate mechanistic research of the biomarkers.

The project also aims to identify new potential targets for pharmacological interventions.


Website: <https://www.metaboadd.eu/>









Total Funding : 704 K€

Duration : 3 years

Coordinator : Iben Lundgaard
 ✉ : iben.lundgaard@med.lu.se



Consortium Members

	Iben Lundgaard	Dept. Of Experimental Medical Science, Lund University (ULUND), Sweden
	Daniel Globisch	Dept. of Chemistry, Uppsala University (UU), Sweden
	Manuel Menéndez-Gonzalez	Hospital: Fundacion para la Investigacion Sanitaria del Principado de Asturias (FINBA), Spain
	Ines Thiele	School of Medicine, University of Galway, Ireland (NUI), Ireland
	Tamas Letoha	Company: Pharmacoidea, Szeged (PHI), Hungary
	Rezzan Gülhan	Dept. of Medical Pharmacology, Marmara University School of Medicine (MUSM), Turkey